BAM
CADL icon

Belpointe Asset Management’s Candel Therapeutics CADL Stock Holding History

Belpointe Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Buy
+45,604
New +$248K 0.01% 968

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belpointe Asset Management's CADL Position: Q1 2026 in Review

Belpointe Asset Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 45,604 shares worth $223K. The stake represents 0.01% of the portfolio and ranks #968 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Belpointe Asset Management held 45,604 shares of Candel Therapeutics worth $223K as of Q1 2026.
  • Candel Therapeutics was a new Belpointe Asset Management position in Q1 2026.
  • Candel Therapeutics made up 0.01% of Belpointe Asset Management's portfolio in Q1 2026, its #968 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.